Qiu et al., who identified DKK-1 as a potential predictor of sorafenib effectiveness, used a panel of 81 HCC cell lines from the Liver Cancer Model Repository to show that FGFR inhibitors including lenvatinib had a favorable effect on HCC strains with the amplification of FGFR and FGF. The gene discussed is DKK1; the disease is hepatocellular carcinoma.